Low-Dose Naltrexone (LDN 1.5-4.5mg)
Low-Dose Naltrexone (LDN 1.5-4.5mg) risk profile, scheduling, and guidance for claims professionals and care workers .
Low-Dose Naltrexone (LDN 1.5-4.5mg) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Off-label use of naltrexone at micro-doses for chronic pain, fibromyalgia. Growing evidence. CAUTION: contraindicated with opioids.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Off-label use of naltrexone at micro-doses for chronic pain, fibromyalgia. Growing evidence. CAUTION: contraindicated with opioids.
Regulatory and Compliance Guidance
When Low-Dose Naltrexone (LDN 1.5-4.5mg) appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- r/LowDoseNaltrexone — Patient experience community (2024)
Active community of LDN users sharing experiences. Common themes: fibromyalgia, autoimmune conditions, chronic pain. Anecdotal reports of benefit.
Anecdotal — self-selected positive reports, no controlled outcomes
- Low-dose naltrexone for chronic pain: systematic review (2018)
Systematic review finding preliminary evidence for LDN in fibromyalgia and chronic pain. Small trials, heterogeneous outcomes. More research needed.
Peer-reviewed but evidence graded as low quality
- Low-dose naltrexone for fibromyalgia — pilot RCT (2013)
Small RCT (n=31) showing LDN 4.5mg reduced fibromyalgia pain by 28.8% vs placebo. Stanford study.
Published RCT but very small sample size
- Peter Attia — LDN and autoimmune conditions (2023)
Discussion of LDN mechanisms (TLR4 antagonism, endorphin upregulation) and clinical applications. Notes it is well-tolerated but evidence base is thin.
Physician communicator — reasonable discussion of evidence gaps
Need to assess this medication across your caseload?
Run a full risk assessment including Low-Dose Naltrexone (LDN 1.5-4.5mg) interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.